Clin2
NCT07688928Possibly a fitRecruiting

Finerenone vs spironolactone for high blood pressure from aldosteronism

Primary AldosteronismEndocrine Hypertension

Treatments studied

Part of Hormones & metabolism clinical trials.

This trial compares two medicines, finerenone and spironolactone, to see which works better and is safer for lowering blood pressure in people with primary aldosteronism. It may help you if you have high blood pressure caused by too much aldosterone.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
104 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have high blood pressure (above 140/90) and have been diagnosed with primary aldosteronism.
  • Your potassium level is at least 2.5, but no higher than 5 (based on a recent blood test).
  • You do not have serious kidney disease (eGFR at least 60).
  • You can avoid certain medications (like some antibiotics, antifungals, or seizure drugs) for 2 weeks before and during the trial.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06457074Recruiting· Phase 4
Finerenone for primary aldosteronism (FAIRY trial)

This trial tests a drug called finerenone for people with a specific cause of high blood pressure (primary aldosteronism). It aims to see if finerenone can help lower blood pressure and improve hormone levels better than current care.

Chongqing, Chongqing Municipality
NCT07137364Recruiting
Testing spironolactone with blood pressure drugs for PA

This trial looks at whether adding spironolactone to your current blood pressure medicines works better for people with primary aldosteronism (a condition where your adrenal glands make too much aldosterone, raising blood pressure). You may qualify if you have this form of high blood pressure but have declined surgery or don't have an adenoma.

Chongqing, Chongqing Municipality
NCT05030545Recruiting· Phase 4
PET/CT study of spironolactone or eplerenone in primary aldosteronism

This study looks at how primary aldosteronism affects the heart and blood vessels, and whether blocking its hormone signal (with spironolactone or eplerenone) changes those findings on imaging tests. It is small and focuses on people with confirmed or suspected primary aldosteronism who are being followed for heart health.

Boston, Massachusetts
NCT04409431Recruiting
Spironolactone plus adrenal nerve treatment for adrenal overactivity

This trial studies whether blocking part of the adrenal blood supply (“adrenal artery ablation”) along with spironolactone can improve hormone-driven high blood pressure caused by primary aldosteronism. It may help people who have confirmed adrenal overactivity and do not want surgery.

Chongqing, Chongqing Municipality
NCT05561361Recruiting
Test treatment for primary aldosteronism and blood vessel function

This trial studies whether a specific treatment (related to spironolactone/aldosterone support) can improve how well your blood vessels work in people with primary aldosteronism. It may help reduce blood pressure risk by improving blood vessel health.

Nanchang
NCT06108427Recruiting
Renin-guided treatment with aldosterone blockers in primary aldosteronism

This study tests whether adjusting a type of blood pressure medication (called a mineralocorticoid receptor antagonist) based on renin levels is safe and helpful for people with primary aldosteronism. It aims to find a better way to manage the condition.

Montreal, Quebec

Hear when a new Primary Aldosteronism trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.